Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of Peking University(Health Sciences) ; (6)2004.
Article in Chinese | WPRIM | ID: wpr-565414

ABSTRACT

Objective:To longitudinally analyze the unit costs and technical efficiency of human immunodeficiency virus(HIV) voluntary counseling and testing in China.Methods:Unit costs were calcula-ted by the province and period using longitudinal data from 7 provinces covered by Global Fund China AIDS Program Round 3,and then technical efficiency and Malmquist indices were measured with an approach to data envelopment analysis.Results:The unit costs for HIV voluntary counseling and testing changed dramatically over a 3+-year period,decreasing from $165.97(mean) to $53.41,with an accumulative unit cost of $67.19,and its technical efficiency was averaging between 0.44 and 0.63.Conclusion:The time series of unit costs for HIV voluntary counseling and testing formed a U-shape curve with an inflection point before which unit costs dramatically dropped and another inflection point beyond which unit costs went up.These findings can inform program managers of the changing unit costs when extending or expanding HIV prevention efforts.

2.
Chinese Medical Journal ; (24): 15-19, 2003.
Article in English | WPRIM | ID: wpr-356878

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the roles of folic acid and beta-carotene in the chemoprevention of gastric and other gastrointestinal (GI) cancers.</p><p><b>METHODS</b>In a randomized, double-blind, placebo-controlled trial, a total of 216 patients with atrophic gastritis were randomly assigned to one of the four groups: (1) folate (FA, 20 mg per day plus vitamin B(12) 1 mg, intramuscularly, per month for one year, then 20 mg two times a week plus 1 mg per three months for the next year); (2) natural beta-carotene (N-betaC, 30 mg per day for first year, then 30 mg two times a week for the next); (3) synthetic beta-carotene (S-betaC, administered as in N-betaC); and (4) placebo. Follow-ups continued from 1994 to 2001.</p><p><b>RESULTS</b>A total of 7 new cases of gastrointestinal cancers were diagnosed with 3 stomach, 1 colon and 1 esophageal cancers occurring in the placebo group; 1 stomach cancer in both of the N-betaC and S-betaC groups, and no cancer occurring in FA group. In terms of GI cancers, there was a significant reduction in the FA group, compared with the placebo group (P = 0.04). A similar trend was observed in both N-betaC and S-betaC groups (P = 0.07 - 0.08). Taken together, the three intervention groups displayed a highly significant decrease in occurrence (P = 0.004, vs placebo), and a lower risk for GI cancers (OR = 0.12; 95% confidence interval, 0.03 - 0.51). For development of gastric cancer, any one of the three active-treated groups did not reach statistically significant reduction. The FA group showed obvious improvement of the gastric mucosal lesions with more patients displaying lesions reversed or stable atrophy and inflammation (P = 0.04), reversed intestinal metaplasia (P = 0.06) at the end of follow-up, and reversed displasia (P = 0.017) at 12 months. Two cases of false jaundice were found in beta-carotene groups with no influence on administration, and no side-effects were reported in FA group.</p><p><b>CONCLUSIONS</b>This trial revealed the interventional effect of folic acid on the development of GI cancers, a similar effect of beta-carotene was also detected. Also, folic acid may be of use to treat atrophic gastritis by preventing or reversing the precancerous lesions.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Anticarcinogenic Agents , Therapeutic Uses , Double-Blind Method , Folic Acid , Therapeutic Uses , Gastric Mucosa , Pathology , Gastrointestinal Neoplasms , Patient Compliance , Stomach Neoplasms , beta Carotene , Therapeutic Uses
SELECTION OF CITATIONS
SEARCH DETAIL